Clinical trial
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema…
NCT00401115 · Santen Inc., Industry · Completed
Key facts
| NCT number | NCT00401115 |
|---|---|
| Title | Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy |
| Official title | A Phase 1, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy |
| Lead sponsor | Santen Inc., Industry |
| Collaborators | MacuSight, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema, Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | MS-R001 (rapamycin) |
| Enrollment | 50 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 17, 2006 |
| Last update posted | Jul 26, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: